Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System

• Main Authors: Stefan Milutinovic (Author), Predrag Jancic (Author), Vera Jokic (Author), Marija Petrovic (Author), Igor Dumic (Author), Ambar Morales Rodriguez (Author), Nikola Tanasijevic (Author), Dustin Begosh-Mayne (Author), Dragana Stanojevic (Author), Ricardo O. Escarcega (Author), Juan Lopez-Mattei (Author), Xiangkun Cao (Author)
• Format: Book
• Published: MDPI AG, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other...